Deals channel feed – Endpoints News

Deals channel feed

Lotte Group turns to Merck KGaA’s US unit for leg up at new Syracuse biologics plant

3 years ago

Urovant hops across the pond, out-licensing overactive bladder drug to Pierre Fabre for $75M

3 years ago

Bill Haney's latest startup scores deal from Sanofi, its newest Big Pharma partner, with $54M upfront

3 years ago

Pfizer lines up access to 'doggybone DNA' in manufacturing of mRNA vaccines, gene therapies and more

3 years ago

Bourla called and Coric answered: Pfizer's offer for Biohaven slid $10.50 per share in under 30 days but added spinoff funds, royalties

3 years ago

Bruised Syros scores $130M PIPE from marquee group — while grabbing $60M cash from all-stock merger

3 years ago

Hitching a quick ride on the M&A train, AstraZeneca wagers $100M cash on T cell engager

3 years ago

Otsuka pays Akebia $55M to formally end vadadustat partnership, waving goodbye to the $1B deal

3 years ago

Amgen sells its Turkish manufacturing arm for $135M

3 years ago

Astellas subsidiary to partner with Pittsburgh upstart in search for 'undruggable' proteins

3 years ago

Basilea tosses an oncology drug back to Merck, doubling down on antibiotics in revamp

3 years ago

Years after linking arms with Bristol Myers and both Mercks, Sutro finds its latest partner in Tokyo

3 years ago

Pharma group bets up to $1B-plus on the PhIII resurrection of a once dead-and-buried LDL drug

3 years ago

A Merck partner is sucked into the financial quagmire as key lender calls in a note

3 years ago

Ipsen snags an approved cancer drug in $247M M&A deal as another battered biotech sells cheap

3 years ago

VC firms take osteoporosis drugmaker Radius Health private for almost $900M

3 years ago

CAR-T in, IPF drug out: Galapagos bails on biotech partnership amid pipeline revamp

3 years ago

F-star bought out in $161M all-cash deal as Hong Kong's Sino Biopharm looks toward international expansion

3 years ago

In lieu of hard M&A news, one group of analysts crunches the numbers around a $40B Seagen buy

3 years ago

In pursuit of accessible sickle cell cure, Novartis inks $1.5B deal to tap Precision's ARCUS gene editing tech

3 years ago

AbbVie walks away from Morphic deal in aftermath of safety signal in preclinical testing

3 years ago

Galapagos CEO Paul Stoffels bets €225M on a new CAR-T strategy for the long suffering biotech

3 years ago

Pfizer nabs $95M stake in Valneva as Lyme disease vaccine approaches pivotal study

3 years ago

Rhythm gets second OK for genetic obesity drug Imcivree, swings into royalty deal

3 years ago

First page Previous page 55 56 575859 60 61 Next page Last page